- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
Radiotherapy and immunotherapy removing extramedullary red blood cell precursor cells.
Radiotherapy and immunotherapy removing extramedullary red blood cell precursor cells. Science Sub-Journal: Revealing that radiotherapy and immunotherapy restrict tumor progression by removing extramedullary red blood cell precursor cells.
Targeted radiation is often used to research and treat different types of cancer. In a new study, researchers from China’s Xi’an Jiaotong University, Shandong First Medical University, Shandong Qianfoshan Hospital, Xuzhou Medical University, the University of Chicago, and the University of Texas Southwestern Medical Center focused on one type of cell , They release a protein that enhances resistance to cancer therapy and promotes tumor progression. The relevant research results were published in the journal “Science Translational Medicine” on February 24, 2021, with the title of “Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity”.
This research focused on Ter cells, which are extra medullary erythroid precurser cells that secrete the neuropeptide artemin. These researchers found that local tumor radiotherapy, systemic immunotherapy or a combination of these two treatment methods can deplete Ter cells in the spleen, reduce the production of artemin, and limit the progression of locally irradiated tumors and tumors outside the radiation field.
Dr. Ralph Weichselbaum, co-corresponding author of the paper and Chair of Radiation and Cellular Oncology at the University of Chicago, said that the several targets identified in these studies may “potentially improve outcomes after radiotherapy and immunotherapy. The prospects for these methods are exciting.” .
This study uses animal models and samples from three different groups of patients who have received a combination of radiotherapy and chemotherapy, immunotherapy and radioimmunotherapy for the treatment of various cancers including lung cancer and melanoma.
According to these researchers, the combination of Ter cell depletion, blocking artemin signal transduction, and immunotherapy resulted in increased control of tumor burden in mice. They pointed out that Ter cell depletion depends on a complete adaptive immune response mediated by interferon gamma.
Weichselbaum said that the artemin pathway targeting Ter cells “enhanced the efficacy of immunotherapy in the model system.” The decrease in the number of Ter cells and the decrease in the expression of artemin and artemin signaling partners are related to the improvement of the efficacy of patients receiving radiotherapy, radioimmunotherapy and immunotherapy.
These researchers proposed, “In short, our research confirms the opposing regulatory effects between radiotherapy or immunotherapy and tumor-induced splenic Ter cells.”
These researchers believe that these immunotherapies and combined treatments with radiotherapy are “worthy of further study to understand their interaction with tumor-promoting pathways.”
(source:internet, reference only)